Quynh Ton is a highly accomplished molecular and cellular developmental biologist with over 10 years of comprehensive experience in research and a robust background in customer relations and communication. With a proven track record in the biotech industry, Quynh has successfully integrated her scientific expertise with business development, focusing on preclinical drug discovery, gene therapy, and antibody development. Her commitment to advancing scientific knowledge and delivering innovative solutions makes her a valuable asset to any organization.

Quynh earned her Ph.D. in Molecular/Cellular Biology from Lehigh University, where she developed a strong foundation in scientific research and methodology. She also holds a B.S. in Biology from Bard College and an A.S. in Health Sciences from North Shore Community College. This solid educational background, combined with her practical experience, positions her as a knowledgeable leader in her field.

Throughout her career, Quynh has held various pivotal roles, including Business Development Manager at PathoQuest, where she was responsible for leading genome testing NGS portfolio initiatives across the West Coast, Southwest, and Midwest territories. Her strategic approach to client acquisition resulted in securing contracts valued at $1.3 million in 2023, showcasing her ability to meet and exceed targets in a competitive environment. Additionally, Quynh served as a Scientific Consultant at Biocellion SPC, where she cultivated relationships within the emerging cultivated meat industry, highlighting her adaptability and innovative thinking.

Quynh’s experience spans several esteemed organizations, including Arbor Biosciences, Eurofins Biopharmaceuticals, and Pharmaron. Her diverse skill set encompasses assay development, quality control, and the implementation of cutting-edge technologies such as CRISPR. Her leadership capabilities were demonstrated when she led a team of scientists in developing bioassay methods and protocols that enhanced research and development initiatives.

Recognized for her contributions to the field, Quynh has been awarded numerous honors, including the NHLBI F32 fellowship and first place in the Annual CYTO Virtual Interactive 2021 Innovation showcase. She has also authored and contributed to several publications, reinforcing her role as a thought leader in molecular and cellular biology.

Quynh’s international exposure includes working with clients in Europe, China, and Singapore, further broadening her perspective on global biotech trends. Fluent in both English and Vietnamese, she is well-equipped to navigate diverse cultural landscapes and foster meaningful collaborations.

In addition to her professional pursuits, Quynh is passionate about yoga, holding certification as a yoga instructor specializing in trauma-informed practices for individuals with Traumatic Brain Injuries. Her commitment to health and wellness reflects her belief in the holistic approach to patient care.

As Quynh seeks board opportunities, her mission remains clear: to cure diseases and expedite the delivery of products and drugs to patients. With her extensive experience and dedication to innovation, she is poised to make significant contributions to any organization she joins.

Character: Quynh Ton embodies integrity and resilience, demonstrating a strong commitment to advancing scientific knowledge and improving patient care.

Knowledge: With over 10 years of experience in molecular and cellular biology, Quynh possesses deep expertise in drug discovery, gene therapy, and antibody development.

Strategic: Quynh excels in strategic business development, successfully securing significant contracts and driving initiatives within the biotech industry.

Communication: Quynh is adept at fostering relationships and conveying complex scientific concepts clearly, facilitating collaboration across diverse teams and stakeholders.